A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Trial Profile

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Selinexor (Primary)
  • Indications Liposarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAL
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 05 Jun 2018 Phase II results of SEAL trial (n=56) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 15 Mar 2018 According to a Karyopharm Therapeutics media release, Company intends to use the data from the Phase 2/3 SEAL study to support a New Drug Application in the U.S. and a Marketing Authorization Application (MAA) in Europe for oral selinexor as a potential new treatment for patients with advanced unresectable dedifferentiated liposarcoma.
    • 29 Nov 2017 Planned End Date changed from 1 Jul 2019 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top